DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Influence of quercetin supplementation on disease risk factors in community-dwelling adults.

Author(s): Knab AM, Shanely RA, Henson DA, Jin F, Heinz SA, Austin MD, Nieman DC

Affiliation(s): Appalachian State University, Kannapolis, NC, USA.

Publication date & source: 2011-04, J Am Diet Assoc., 111(4):542-9.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

BACKGROUND: In vitro data indicate quercetin has antioxidative and anti-inflammatory functions with the potential to lower disease risk factors, but data in human beings are limited. OBJECTIVE: The objective of this study was to investigate the effect of quercetin, vitamin C, and niacin supplements (500 mg quercetin, 125 mg vitamin C, and 5 mg niacin [Q-500]; 1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin [Q-1,000]), on disease risk factors in a large group of community adults (n=1,002, 60% women) varying widely in age and body mass index. DESIGN: Subjects were randomized into one of three groups (placebo, Q-500, or Q-1,000) and ingested supplements for 12 weeks. Blood samples were taken pre- and postsupplementation, and plasma quercetin, inflammatory markers (ie, C-reactive protein and five cytokines), diagnostic blood chemistries, blood pressure, and blood lipid profiles were measured. RESULTS: Plasma quercetin increased in the Q-500 and Q-1,000 groups. No differences in blood chemistries were found except for a small decrease in serum creatinine and increase in glomerular filtration rate in Q-500 and Q-1,000 groups. A small decrease in mean arterial blood pressure was measured for Q-500 and Q-1,000 groups compared to placebo. A difference in serum total cholesterol was measured between Q-500 and placebo groups, and there was small decrease in high-density lipoprotein cholesterol levels in the Q-1,000 group. Change in inflammatory measures did not differ between groups except for a slight decrease in interleukin-6 for the Q-1,000 group. CONCLUSIONS: Q-500 or Q-1,000 supplementation for 12 weeks had a negligible influence on disease risk factors. Copyright (c) 2011 American Dietetic Association. Published by Elsevier Inc. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017